MBX Biosciences (MBX) Current Leases (2023 - 2026)
MBX Biosciences (MBX) posted Current Leases of $178000.0 for Q1 2026, up 3.49% sequentially from $172000.0 in Q4 2025, and up 36.92% YoY from $130000.0 in Q1 2025.
MBX Biosciences (MBX) Current Leases (2023 - 2026) Analysis & Trends
MBX Biosciences has reported Current Leases for 4 years, with the latest figure at $178000.0 in Q1 2026.
- Quarterly Current Leases rose 36.92% year-over-year to $178000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $178000.0 (up 36.92% YoY) and the FY2025 annual result came in at $172000.0, up 0.58% from the prior year.
- Current Leases rose to $178000.0 in Q1 2026 per MBX's latest filing, from $172000.0 in the prior quarter.
- Over five years, Current Leases peaked at $178000.0 in Q1 2026 and troughed at $130000.0 in Q1 2025.
- A 4-year average of $157750.0 and a median of $160000.0 in 2024 frame the typical range for Current Leases.
- The sharpest annual moves came in 2025 and 2026: Current Leases fell 7.23% in 2025, then soared 36.92% in 2026.
- Over 4 years, Current Leases stood at $153000.0 in 2023, then grew by 11.76% to $171000.0 in 2024, then grew by 0.58% to $172000.0 in 2025, then increased by 3.49% to $178000.0 in 2026.
- According to Business Quant data, Current Leases over the past three periods registered $178000.0, $172000.0, and $154000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | MBX Biosciences | 3.29 Bn | 3.29 Bn | - | 631,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 631,000.00 |
| Mar 31, 2026 | 178,000.00 |
| Dec 31, 2025 | 172,000.00 |
| Sep 30, 2025 | 154,000.00 |
| Jun 30, 2025 | 138,000.00 |
| Mar 31, 2025 | 130,000.00 |
| Dec 31, 2024 | 171,000.00 |
| Sep 30, 2024 | 166,000.00 |
| Dec 31, 2023 | 153,000.00 |